LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Начало・Списък с акции・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

38.18 0.45

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

37.28

Максимум

38.26

Ключови измерители
By Trading Economics
Приходи	-6.2M -91M
Марж на печалбата	-867.293
Служители	316
EBITDA	-2.7M -96M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+45.14% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-59M 3.2B
Предишно отваряне	37.73
Предишно затваряне	38.18

Настроения в новините

By Acuity

60%

40%

323 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

34.81 / 38.24 Подкрепа & съпротива

Xenon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.11.2025 г., 21:06 ч. UTC

Значими двигатели на пазара

JBS Down After Trump Calls for Probe into Meat-Packing Companies

7.11.2025 г., 22:36 ч. UTC

Печалби

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7.11.2025 г., 22:22 ч. UTC

Печалби

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q Rev $2.95B >CSU.T

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q Net $210M >CSU.T

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q EPS $9.89 >CSU.T

7.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

7.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

7.11.2025 г., 20:59 ч. UTC

Печалби

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7.11.2025 г., 20:26 ч. UTC

Пазарно говорене

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7.11.2025 г., 20:22 ч. UTC

Печалби

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7.11.2025 г., 20:04 ч. UTC

Пазарно говорене

Oil Futures Close Choppy Week With Losses -- Market Talk

7.11.2025 г., 19:34 ч. UTC

Пазарно говорене

Gold Posts Small Gain for Week -- Market Talk

7.11.2025 г., 19:31 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7.11.2025 г., 19:17 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7.11.2025 г., 19:09 ч. UTC

Печалби

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7.11.2025 г., 19:08 ч. UTC

Печалби

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7.11.2025 г., 18:31 ч. UTC

Пазарно говорене

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7.11.2025 г., 17:27 ч. UTC

Пазарно говорене

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

7.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

7.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

7.11.2025 г., 17:17 ч. UTC

Придобивния, сливания и поглъщания

Satair Expects to Complete Purchase in Early 2026

7.11.2025 г., 17:17 ч. UTC

Придобивния, сливания и поглъщания

Satair: Deal Includes Unical's and ecube's Seven Operational Sites and Offices, With Combined 2024 Rev of $298M and Headcount of 413

7.11.2025 г., 17:15 ч. UTC

Придобивния, сливания и поглъщания

Airbus Unit Satair to Buy Unical Aviation From Platinum Equity

7.11.2025 г., 17:09 ч. UTC

Пазарно говорене

PENN Is Falling Further Behind Competitors -- Market Talk

7.11.2025 г., 16:49 ч. UTC

Пазарно говорене

Losing ESPN Partnership Will Hurt PENN -- Market Talk

7.11.2025 г., 16:24 ч. UTC

Пазарно говорене

OPEC+'s Output Hike Pause Comes Amid Excess Supply, Lower Spare Capacity -- Market Talk

7.11.2025 г., 16:17 ч. UTC

Пазарно говорене

Oil Market Faces Oversupply But "Glut" Might Be Overblown -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Xenon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

45.14% нагоре

12-месечна прогноза

Среден 55.59 USD 45.14%

Висок 65 USD

Нисък 44 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за Xenon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

15 ratings

Купи

Задържане

Продай

Според 15 анализатори, дали борсови рейтинги на Xenon Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

34.81 / 38.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

323 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.